Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.

Albright AV, Erickson-Viitanen S, O'Connor M, Frank I, Rayner MM, González-Scarano F.

AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1527-37.

PMID:
11054266
2.

The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.

Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP.

Bioorg Med Chem Lett. 1998 Apr 7;8(7):823-8.

PMID:
9871548
3.

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.

Jadhav PK, Woerner FJ, Lam PY, Hodge CN, Eyermann CJ, Man HW, Daneker WF, Bacheler LT, Rayner MM, Meek JL, Erickson-Viitanen S, Jackson DA, Calabrese JC, Schadt M, Chang CH.

J Med Chem. 1998 Apr 23;41(9):1446-55.

PMID:
9554878
4.

Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.

Rayner MM, Cordova B, Jackson DA.

Virology. 1997 Sep 15;236(1):85-94.

5.

Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Sheng N, Pettit SC, Tritch RJ, Ozturk DH, Rayner MM, Swanstrom R, Erickson-Viitanen S.

J Virol. 1997 Aug;71(8):5723-32.

6.

Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.

De Lucca GV, Liang J, Aldrich PE, Calabrese J, Cordova B, Klabe RM, Rayner MM, Chang CH.

J Med Chem. 1997 May 23;40(11):1707-9.

PMID:
9171880
7.

Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.

Winslow DL, Garber S, Reid C, Scarnati H, Baker D, Rayner MM, Anton ED.

AIDS. 1996 Sep;10(11):1205-9.

PMID:
8883581
8.

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.

Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang CH, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Hodge CN, et al.

J Med Chem. 1996 Aug 30;39(18):3514-25.

PMID:
8784449
9.

Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.

Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, Jadhav PK, De Lucca GV, Smyser TE, Klabe RM, Bacheler LT, Rayner MM, Seitz SP.

J Med Chem. 1996 May 24;39(11):2156-69.

PMID:
8667359
10.

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, Grubb M, Jackson DA, Jadhav PK, Korant B, Lam PY, Maurin MB, Meek JL, Otto MJ, Rayner MM, Reid C, Sharpe TR, Shum L, Winslow DL, Erickson-Viitanen S.

Chem Biol. 1996 Apr;3(4):301-14.

11.
12.

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

Lam PY, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN, et al.

Science. 1994 Jan 21;263(5145):380-4.

PMID:
8278812
13.

In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.

Otto MJ, Reid CD, Garber S, Lam PY, Scarnati H, Bacheler LT, Rayner MM, Winslow DL.

Antimicrob Agents Chemother. 1993 Dec;37(12):2606-11.

Supplemental Content

Loading ...
Support Center